Santé connectée / Connected health « Servier teste 4 solutions connectées en vie réelle à l’hôpital » Lancée en novembre 2016, WeHealth™ Digital Medicine se distingue par son approche d’open innovation en e-santé pour co-développer son portefeuille avec des start-ups. Quelles solutions digitales et commercialisation à l’hôpital. L’équipe connectées pouvez-vous nous multidisciplinaire Wehealth™ est présenter ? ensuite présente à toutes les étapes du processus qui va conduire à la mise David Guez : à disposition de ces solutions. Nous sommes ainsi déjà passés des essais cli- Aujourd’hui, nous avons signé 13 par- niques à la vie réelle pour Cardioskin™, tenariats avec des sociétés innovantes notre solution de textile connecté David Guez, Executive Director, Innovation dans les domaines de la cardiologie, co-développée avec Bioserenity pour le & Scouting de WeHealth™ Digital Medicine l’oncologie, la neurologie et la dia- monitoring ECG, qui propose un enre- David Guez, Executive Director, Innovation bétologie, aboutissant à 4 dispositifs gistrement de longue durée en ambu- & Scouting de WeHealth™ Digital Medicine numériques et plateformes connectées latoire. Une centaine de patients est en en phase précoce d’adoption et de train de la tester en remplacement du ”Servier is testing 4 connected solutions in real life setting, at the hospital” Launched in November 2016, WeHealth™ Digital Medicine stands out through its e-health open innovation approach in co-developing its portfolio with start-ups. What digital and these solutions available. We have already of chronic heart failure relapses. Nearly connected solutions can you moved away from clinical trials to the 500 patients have already benefited from present to us? real-life phase for our Cardioskin™, a monitoring during hospitalization or connected textile solution co-developed when visiting their family doctor. And David Guez: with Bioserenity for ECG monitoring, our portfolio includes two other onco- which ensures long-term outpatient logy platforms: On’cohub™ (Ocelian™ Today, we have entered 13 partnerships recording. A hundred patients are cur- in the United States), which was co-de- with innovative companies in the fields rently testing it as a replacement solutionveloped with DeepLink Medical with a of cardiology, oncology, neurology and for the 24-hour ECG Holter monitor in view to monitoring and helping evaluate diabetes, resulting in 4 digital devices cardiology, at La Salpêtrière Hospital treatment response in solid tumours, and connected platforms which are in the (Paris). We have also co-developed with and Bionov™, which offers therapeutic early stage of adoption and commerciali- NP Medical, the Satelia® Cardiology decision support enabling oncologists to zation in hospitals. The multidisciplinary (HeartKeeper™ outside France) remote individualize treatment mainly based on team Wehealth™ is present in all stages monitoring platform, our goal being to analysing a patient’s genomic data. Bio- of the process that will lead to making allow for the early detection of symptoms nov™, which has been co-developed with 58The Pharmaceutical Post 01 / Janvier - 2020